BRIEF-Tff Pharmaceuticals Announces Updated Data From The Tacrolimus Inhalation Powder (TFF TAC) and Voriconazole Inhalation Powder (TFF VORI) Clinical Programs

Reuters03-28

March 27 (Reuters) - TFF Pharmaceuticals Inc :

* TFF PHARMACEUTICALS ANNOUNCES UPDATED DATA FROM THE TACROLIMUS INHALATION POWDER (TFF TAC) AND VORICONAZOLE INHALATION POWDER (TFF VORI) CLINICAL PROGRAMS

* TFF PHARMACEUTICALS INC - DATA FROM TFF VORI PHASE 2 AND EAP PROGRAM CONTINUE TO DEMONSTRATE ANTIFUNGAL ACTIVITY AND A FAVORABLE SAFETY AND TOLERABILITY PROFILE

* TFF PHARMACEUTICALS INC - INTERIM CLINICAL DATA SUGGESTING THAT EACH PRODUCT CAN BE DELIVERED SAFELY AND EFFICACIOUSLY INTO LUNGS

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2422925163?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-03-28 04:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2422925163","market":"us","top_or_hot":-1,"title":"BRIEF-Tff Pharmaceuticals Announces Updated Data From The Tacrolimus Inhalation Powder (TFF TAC) and Voriconazole Inhalation Powder (TFF VORI) Clinical Programs","media":"Reuters","content":"<html><body><p>March 27 (Reuters) - <a href=\"https://laohu8.com/S/TFFP\">TFF Pharmaceuticals</a> Inc   :</p><p>   * TFF PHARMACEUTICALS ANNOUNCES UPDATED DATA FROM THE TACROLIMUS INHALATION POWDER (TFF TAC) AND VORICONAZOLE INHALATION POWDER (TFF VORI) CLINICAL PROGRAMS</p><p>   * TFF PHARMACEUTICALS INC - DATA FROM TFF VORI PHASE 2 AND EAP PROGRAM CONTINUE TO DEMONSTRATE ANTIFUNGAL ACTIVITY AND A FAVORABLE SAFETY AND TOLERABILITY PROFILE</p><p>   * TFF PHARMACEUTICALS INC - INTERIM CLINICAL DATA SUGGESTING THAT EACH PRODUCT CAN BE DELIVERED SAFELY AND EFFICACIOUSLY INTO LUNGS</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Tff Pharmaceuticals Announces Updated Data From The Tacrolimus Inhalation Powder (TFF TAC) and Voriconazole Inhalation Powder (TFF VORI) Clinical Programs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Tff Pharmaceuticals Announces Updated Data From The Tacrolimus Inhalation Powder (TFF TAC) and Voriconazole Inhalation Powder (TFF VORI) Clinical Programs\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-03-28 04:18 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>March 27 (Reuters) - TFF Pharmaceuticals Inc   :   * TFF PHARMACEUTICALS ANNOUNCES UPDATED DATA FROM THE TACROLIMUS INHALATION POWDER (TFF TAC) AND VORICONAZOLE INHALATION POWDER (TFF VORI) CLINICAL ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4105","symbol_name":"独立电力生产商与能源贸易商","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2422925163","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2422925163","pubTimestamp":1711570724,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"March 27  - TFF Pharmaceuticals Inc   :   * TFF PHARMACEUTICALS ANNOUNCES UPDATED DATA FROM THE TACROLIMUS INHALATION POWDER  AND VORICONAZOLE INHALATION POWDER  CLINICAL PROGRAMS   * TFF PHARMACEUTICALS INC - DATA FROM TFF VORI PHASE 2 AND EAP PROGRAM CONTINUE TO DEMONSTRATE ANTIFUNGAL ACTIVITY AND A FAVORABLE SAFETY AND TOLERABILITY PROFILE   * TFF PHARMACEUTICALS INC - INTERIM CLINICAL DATA SUGGESTING THAT EACH PRODUCT CAN BE DELIVERED SAFELY AND EFFICACIOUSLY INTO LUNGSSource text for Eikon:    Further company coverage:    ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4105":"独立电力生产商与能源贸易商","BK4007":"制药","TFFP":"TFF Pharmaceuticals","TAC":"Transalta Corp"},"translate_title":"简介—TFF制药公司公布他克莫司吸入粉剂（TFF TAC）和伏立康唑吸入粉剂（TFF VORI）临床项目的最新数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TAC":1,"TFFP":0.9},"content_text":"March 27 (Reuters) - TFF Pharmaceuticals Inc   :   * TFF PHARMACEUTICALS ANNOUNCES UPDATED DATA FROM THE TACROLIMUS INHALATION POWDER (TFF TAC) AND VORICONAZOLE INHALATION POWDER (TFF VORI) CLINICAL PROGRAMS   * TFF PHARMACEUTICALS INC - DATA FROM TFF VORI PHASE 2 AND EAP PROGRAM CONTINUE TO DEMONSTRATE ANTIFUNGAL ACTIVITY AND A FAVORABLE SAFETY AND TOLERABILITY PROFILE   * TFF PHARMACEUTICALS INC - INTERIM CLINICAL DATA SUGGESTING THAT EACH PRODUCT CAN BE DELIVERED SAFELY AND EFFICACIOUSLY INTO LUNGSSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2422925163"}